IP Library › Granted Patent US 9,090,889
Granted Patent B2
US 9,090,889 · App. 13/948,956 · Granted Jul 28, 2015

Xylose isomerases and their uses

Inventors: David Neal Nunn, Jr. (Carlsbad, CA); Peter Luginbuhl (San Diego, CA); Ling Li (San Diego, CA); Adam Martin Burja (San Diego, CA); Jon Peter Flash Bartnek (San Diego, CA)
Assignee: BP Corporation North America Inc.
C12N9/90C12N9/92C12P7/06C12P7/16C12P7/18C12P7/20C12P7/40C12P7/649C12P13/04C12P17/184C12P35/06C12Y503/01005C12P2203/00Y02E50/10Y02E50/13Y02E50/16Y02E50/17Y02E50/343
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,889
App. No.
13/948,956
Granted
Jul 28, 2015
Kind
B2
Abstract

This disclosure relates to novel xylose isomerases and their uses, particularly in fermentation processes that employ xylose-containing media.

Claims (47)

1. An isolated nucleic acid sequence which encodes a polypeptide comprising an amino acid sequence having at least 95%, 97% or 98% sequence identity to amino acid residues 2-377 of SEQ ID NO:96, wherein the nucleic acid encodes a polypeptide with at least one substitution relative to SEQ ID NO: 96 or at least one heterologous amino acid flanking the N-terminal or the C-terminal.

2. An isolated nucleic acid sequence having at least 90%, 93%, 95%, 96%, 98%, or 99% sequence identity, or having 100% sequence identity, to the nucleotide sequence of SEQ ID NO: 95, or to a portion thereof and encoding a xylose isomerase catalytic or dimerization domain, wherein the nucleic acid comprises at least one substitution relative to SEQ ID NO: 95 or is codon optimized.

3. A vector comprising the nucleic acid sequence of claim 2 .

4. The vector of claim 3 which further comprises an origin of replication.

5. The vector of claim 3 , which further comprises a promoter sequence operably linked to said nucleic acid sequence.

6. The vector of claim 5 , wherein the promoter sequence is operable in yeast.

7. The vector of claim 5 , wherein the promoter sequence is operable in filamentous fungi.

8. The nucleic acid sequence of claim 1 or 2 , further comprising the amino acid sequence of (a) SEQ ID NO:21.2 or SEQ ID NO:213 and/or (b) SEQ ID NO:214.

9. The nucleic acid sequence of claim 8 , wherein the encoded polypeptide comprises an amino acid sequence having at least 95%, 97% or 98% sequence identity to amino acids 2-377 of SEQ ID NO:96.

10. The nucleic acid sequence of claim 8 or 9 , wherein the encoded polypeptide comprises an amino acid sequence having at least 95%, 97% or 98% sequence identity to SEQ ID NO:96.

11. A host cell transformed with the vector of claim 3 .

12. The host cell of claim 11 which is a prokaryotic cell.

13. The host cell of claim 12 which is a bacterial cell.

14. The host cell of claim 11 which is a eukaryotic cell.

15. A recombinant cell engineered to express the polypeptide encoded by the nucleic acid sequence of any one of claims 1 , 2 , 8 , 9 or 10 .

16. The recombinant cell of claim 15 which is a eukaryotic cell.

17. The recombinant cell of claim 15 which is a yeast cell.

18. The recombinant cell of claim 17 which is a yeast cell of the genus Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Klockera, Schwanniomyces, Issatchenkia or Yarrowia.

19. The recombinant cell of claim 18 , wherein the yeast cell is of the species S. cerevisiae, S. bulderi, S. barnetti, S. exiguus, S. uvarum, S. diastaticus, K. lactis, K. marxianus or K. fragili , or Issatchenkia orientalis.

20. The recombinant cell of claim 19 , which is a S. cerevisiae cell.

21. The recombinant cell of claim 20 , comprising one or more genetic modifications resulting in at least one of the following phenotypes:

(a) an increase in transport of xylose into the cell;

(b) an increase in xylulose kinase activity;

(c) an increase in aerobic growth rate on xylose;

(d) an increase in flux through the pentose phosphate pathway into glycolysis;

(e) a decrease in aldose reductase activity;

(f) a decrease in sensitivity to catabolite repression;

(g) an increase in tolerance to ethanol, intermediates, osmolarity or organic acids; and

(h) a reduced production of byproducts.

22. The recombinant cell of claim 21 , wherein one or more genetic modifications result in increased expression levels of one or more of a hexose or pentose transporter, a xylulose kinase, an enzyme from the pentose phosphate pathway, a glycolytic enzyme and an ethanologenic enzyme.

23. The recombinant cell of claim 22 , wherein the increased expression levels are achieved by overexpressing an endogenous gene or expressing a heterologous gene in the recombinant cell.

24. The recombinant cell of claim 21 , wherein one or more genetic modifications result in decreased expression levels of one or more of a hexose kinase gene, the MIGI gene, and the MIG2 genes.

25. The recombinant cell of claim 21 which is engineered to express the xylose reductase (XR), xylose kinase (XK) and xylitol dehydrogenase (XD) pathway.

26. The recombinant cell of claim 17 in which the nucleic acid is operably linked to a promoter that is insensitive to catabolite repression.

27. The recombinant cell of claim 26 in which the promoter is the TDH3 promoter, the PGK1 promoter, the TEF1 promoter, or the ADH1 promoter.

28. The recombinant cell of claim 15 which is a filamentous fungal cell.

29. The recombinant cell of claim 28 , wherein the filamentous fungal cell is of the genus Aspergillus, Penicillium, Rhizopus, Chrysosporium, Myceliophthora, Trichoderma, Humicola, Acremonium or Fusarium.

30. The recombinant cell of claim 28 , wherein the filamentous fungal cell is of the species Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Penicillium chrysogenum, Myceliophthora thermophila , or Rhizopus oryzae.

31. A method for producing a fermentation product, comprising culturing the recombinant cell of claim 15 in medium containing xylose under conditions in which the fermentation product is expressed.

32. The method of claim 31 , wherein the xylose in the medium is provided by lignocellulosic hydrolysate.

33. The method of claim 31 or claim 32 , wherein the fermentation product is ethanol.

34. The method of claim 31 or claim 32 , wherein the fermentation product is butanol, diesel, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1,3-propane-diol, ethylene, glycerol, a β-lactam antibiotic or a cephalosporin.

35. The method of claim 34 , wherein the recombinant cell comprises a genetic modification that results in decreased alcohol dehydrogenase activity.

36. The method of claim 34 or claim 35 , wherein the recombinant cell expresses one or more enzymes that confers on the cell the ability to produce said fermentation product.

37. The method of any one of claims 31 to 36 , wherein the medium further comprises glucose.

38. The method of any One of claims 31 to 36 , wherein the recombinant cell is cultured under anaerobic conditions.

39. The method of any one of claims 31 to 38 , further comprising recovering the fermentation product.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2013
From: BARTNEK, JON PETER FLASH; BURJA, ADAM MARTIN; LUGINBUHL, PETER; NUNN, DAVID NEAL, JR.; LI, LING
To: BP CORPORATION NORTH AMERICA INC.
Reel/Frame 030860/0805 →
Continuity (2)
Provisional Application 61675241 · Jul 24, 2012
Related Publication 20140186884A1 · Jul 3, 2014